Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE  
Europese Commissie, DG COMP MERG ER REGISTRY, 1049 Brussel,  BELGIË 
 Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu . 
  EUROPEAN COMMISSION 
Brussels, 1.10.2018 
C(2018) 6520 final 
 
 
To the notifying parties: 
Subject: Case M.8991 – Alphabet/ResMed/JV 
Commission decision pursuant to Articl e 6(1)(b) of Council Regulation (EC) 
No 139/20041 and Article 57 of the Agreement on the European Economic Area2  
Dear Sir or Madam, 
1. On 4 September 2018, the European Commission received notification of a proposed 
concentration pursuant to Article 4 of the Merger Regulation by wh ich the undertakings 
Verily Life Sciences LLC ("Verily", United St ates of America), bel onging to Alphabet Inc. 
("Alphabet", United States of America), an d ResMed Inc. ("ResMed", United States of 
America) acquire within the meaning of Article  3(1)(b) and 3(4) of the Merger Regulation 
joint control of a newly create d joint venture (the "JV"), by way of purchase of shares. The 
JV will study the health and financial imp acts of undiagnosed and untreated sleep apnea 
and other breathing related sleep disorders, an d develop software solutions that enable 
health care providers to more efficiently iden tify, diagnose, treat and manage individuals 
with sleep apnea and other brea thing related sleep disorders.3 
2. The business activities of the undertakings concerned are: 
− for Verily (formerly Google Life Sciences):  research organisation. Google is the 
largest business cont rolled by Alphabet, 
−   for ResMed:  development, manufacturing, distri bution and marketing of medical 
devices and cloud-based software applicat ions that diagnose, treat and manage 
respiratory disorders and other chronic diseases. 
  
                                                 
1 OJ L 24, 29.1.2004, p. 1 (the "Merger Regulation"). With effect from 1 December 2009, the Treaty on the 
Functioning of the European  Union ("TFEU") has introduced certain changes, such as the replacement of 
"Community" by "Union" and "common market" by "inter nal market". The terminology of the TFEU will be 
used throughout this decision.  
2  OJ L 1, 3.1.1994, p. 3 (the "EEA Agreement"). 
3  Publication in the Official Journal of the European Union No C 321 , 11.09.2018, p. 8. 
PUBLIC VERSION 
2 3. After examination of the notification, the Eu ropean Commission ha s concluded that the 
notified operation falls within the scope of the Merger Regulation and of paragraphs 
5(a) and 5(b) of the Commission Notice on a s implified procedure for treatment of certain 
concentrations under Council Regulation (EC) No 139/2004.4 
4. For the reasons set out in the Notice on a simp lified procedure, the European Commission 
has decided not to oppose the notified operati on and to declare it compatible with the 
internal market and with the EEA Agreement. This decision is adopted in application of 
Article 6(1)(b) of the Merger Regulati on and Article 57 of the EEA Agreement. 
For the Commission 
(Signed) 
Johannes LAITENBERGER Director-General   
                                                 
4  OJ C 366, 14.12.2013, p. 5.